Bevasizumab

Bevacizumab is a medication used to treat certain types of cancer. It is a targeted therapy, specifically a monoclonal antibody, that works by inhibiting vascular endothelial growth factor (VEGF). VEGF is a protein that stimulates the growth of new blood vessels, a process called angiogenesis. Tumors require a blood supply to grow and spread, and bevacizumab aims to cut off this supply.

This drug is approved for use in combination with chemotherapy to treat metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, and cervical cancer. It is administered intravenously, typically every two to three weeks, depending on the specific cancer and treatment regimen.

The effectiveness of bevacizumab can vary depending on the type of cancer, the stage of the disease, and individual patient factors. Common side effects can include high blood pressure, fatigue, nosebleeds, and proteinuria (protein in the urine). More serious side effects, though less common, can involve gastrointestinal perforation, bleeding, and impaired wound healing. Regular monitoring by a healthcare professional is essential during treatment with bevacizumab. It is important to discuss the potential benefits and risks with a doctor to determine if bevacizumab is an appropriate treatment option.